INCY News and Press, Incyte Corporation From 05/02/24

2024-05-02 04:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-30 22:00:03 ET Evan David Seigerman from BMO Capital issued a price target of $52.00 for INCY on 2024-04-30 16:29:00. The adjusted price target was set to $52.00. At the time of the announcement, INCY was trading at $52.05. The overall price target consensus is a...

2024-04-30 21:15:01 ET BMO Capital analyst issues MARKET PERFORM recommendation for INCY on April 30, 2024 04:29PM ET. The previous analyst recommendation was Market Perform. INCY was trading at $52.05 at issue of the analyst recommendation. The overall analyst consensus...

2024-04-30 11:43:02 ET Incyte Corporation (INCY) Q1 2024 Earnings Conference Call April 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate VP, IR Hervé Hoppenot - CEO Christiana Stamoulis - CFO Pablo Cagnoni - President, Head of Research &am...

2024-04-30 07:03:19 ET More on Incyte Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) Incyte: A Potential GARP Superstar Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Q1 2024 Earnings Preview Incyte to acquire immune-focu...

LPL Financial Holdings Inc. (LPLA) is expected to report $3.77 for Q1 2024 Banco Santander Brasil SA American Depositary Shares each representing one unit (BSBR) is expected to report $0.14 for Q1 2023 EnLink Midstream LLC representing Limited Partner Interests (ENLC) is expected to repor...

– Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million – O...

2024-04-29 11:44:31 ET More on Incyte Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) Incyte: A Potential GARP Superstar Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte to acquire immune-focused drug developer Escient Incyt...

2024-04-26 16:18:41 ET More on Repare Therapeutics Repare to regain global rights to camonsertib from Roche Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therapeuti...

2024-04-26 13:45:12 ET Summary Incyte Corporation shares have underperformed lately, but the company has shown solid growth, profitability, and increased net cash position. Diversification from its blockbuster drug Jakafi has been slow, but overall appeal has improved. The com...